Teleflex Incorporated, a preeminent worldwide supplier of medical technologies, has announced the full market launch of the highly anticipated UroLift 2 System with Advanced Tissue Control (ATC). Building on the legacy of the original UroLift system, this revolutionary development promises to revolutionize treatment for men suffering symptoms of benign prostatic hyperplasia (BPH) across all prostate sizes - up to 100g.
The UroLift 2 System’s novel ATC feature has recently received clearance from the U.S. Food and Drug Administration (FDA), thereby paving the way for its full-scale market release. The highly sophisticated system is expected to offer enhanced, personalized care to BPH patients across a spectrum of prostate sizes and characteristics.
Teleflex’s UroLift 2 ATC leverages advanced tissue control capabilities, heralding a pivotal step in evolving care standards for BPH. This benign non-cancerous enlargement of the prostate can considerably impact a man’s quality of life, causing symptoms such as increased frequency and urgency of urination.
In addition to this major announcement, Teleflex also expands its product offering with the new Titan SGS Staplerwith Staple Line Reinforcement. This enhanced tool will serve as an additional option for bariatric surgeons, offering amplified reliability and security during bariatric surgical procedures.
The Titan SGS comes with the GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement, a leading-edge technology designed to support and strengthen staple lines, thereby reducing the chances of post-operative complications like bleeding and leaks.
Together, these developments mark a significant stride forward for Teleflex in their commitment to improving patient outcomes and advancing global standards of healthcare through innovative medical technologies.
Comments